Results 271 to 280 of about 64,351 (312)
Some of the next articles are maybe not open access.
Seminars in Cancer Biology, 2022
Triple-negative breast cancer (TNBC) is a broad collection of breast cancer that tests negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein. TNBC is considered to have poorer prognosis than other types of breast cancer because of a lack of effective therapeutic targets ...
Zhan Hua, Jason White, Jianjun Zhou
openaire +2 more sources
Triple-negative breast cancer (TNBC) is a broad collection of breast cancer that tests negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein. TNBC is considered to have poorer prognosis than other types of breast cancer because of a lack of effective therapeutic targets ...
Zhan Hua, Jason White, Jianjun Zhou
openaire +2 more sources
The Achilles heel of TNBCs: Ferroptosis heterogeneity
Cell Metabolism, 2023Resistance to ferroptosis, a form of programmed cell death, is associated with the development of some refractory cancers. In this issue, Yang et al. systematically illustrate the ferroptosis heterogeneity in triple-negative breast cancers (TNBCs) and reveal an innovative immunotherapy combination strategy for the luminal androgen receptor (LAR ...
Li, Jiang, Xiao-Meng, Gao, Ji, Cao
openaire +2 more sources
Accelerating AXL targeting for TNBC therapy
The International Journal of Biochemistry & Cell Biology, 2021The tyrosine kinase receptor AXL of the TAM (TYRO3, AXL and MERTK) family is considered as a promising therapeutic target for different hematological cancers and solid tumors. AXL is involved in multiple pro-tumorigenic processes including cell migration, invasion, epithelial-mesenchymal transition (EMT), and stemness, and recent studies demonstrated ...
Lohit Khera, Sima Lev
openaire +2 more sources
Clinical Breast Cancer, 2016
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer with poor 5-year survival. Knowledge and information about IBC with the triple negative (TNBC) phenotype are limited. Here, we report the characteristics and outcome of inflammatory TNBC (I-TNBC) cancer cohorts from a large TNBC dataset.After obtaining institutional review ...
Tithi Biswas +5 more
openaire +2 more sources
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer with poor 5-year survival. Knowledge and information about IBC with the triple negative (TNBC) phenotype are limited. Here, we report the characteristics and outcome of inflammatory TNBC (I-TNBC) cancer cohorts from a large TNBC dataset.After obtaining institutional review ...
Tithi Biswas +5 more
openaire +2 more sources
Inflammatory TNBC breast cancer: Demography and clinical outcome in a large cohort of TNBC patients.
Journal of Clinical Oncology, 2014e12036 Background: Inflammatory breast cancer is a rare but aggressive form of breast cancer. Even with modern chemotherapy along with multimodality therapy, 5-year survival is poor in the range of 30-50%. Knowledge and information about inflammatory breast cancer with TNBC phenotype are limited.
Tithi Biswas +5 more
openaire +1 more source
Banking on metabolomics for novel therapies in TNBC
Cell Research, 2022Aurelien Tripp, George Poulogiannis
openaire +2 more sources
Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
Pharmaceuticals, 2022Aiswarya Chaudhuri +2 more
exaly